Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 16.1 USD -6.56% Market Closed
Market Cap: 865.9m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-3.3
Current
-7
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-3.3
=
Enterprise Value
301.6m USD
/
EBITDA
-90.4m USD
All Countries
Close
EBITDA Growth
IE
Prothena Corporation PLC
NASDAQ:PRTA
Average EV/EBITDA: 17.7
Negative Multiple: -3.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 460.8 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.6 N/A
AU
CSL Ltd
ASX:CSL
20.7
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -103.9 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.7
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
-0.8

See Also

Discover More